EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

RB-pathway disruption is associated with improved response to neoadjuvant chemotherapy in breast cancer



RB-pathway disruption is associated with improved response to neoadjuvant chemotherapy in breast cancer



Clinical Cancer Research 18(18): 5110-5122




(PDF emailed within 0-6 h: $19.90)

Accession: 055333555

Download citation: RISBibTeXText

PMID: 22811582

DOI: 10.1158/1078-0432.CCR-12-0903



Related references

Neoadjuvant chemotherapy is associated with improved survival compared with adjuvant chemotherapy in patients with triple-negative breast cancer only after complete pathologic response. Annals of Surgical Oncology 19(1): 253-258, 2012

Relationship between the response of breast cancer to neoadjuvant chemotherapy and PI3K/mTOR pathway. Zhonghua Yi Xue Za Zhi 92(34): 2382-2385, 2013

PPAR signaling pathway may be an important predictor of breast cancer response to neoadjuvant chemotherapy. Cancer ChemoTherapy and Pharmacology 70(5): 637-644, 2013

Pathologic complete response to neoadjuvant chemotherapy with trastuzumab predicts for improved survival in women with HER2-overexpressing breast cancer. Annals of Oncology 24(8): 1999-2004, 2014

The nuclear transcription factor kappaB/bcl-2 pathway correlates with pathologic complete response to doxorubicin-based neoadjuvant chemotherapy in human breast cancer. Clinical Cancer Research 11(23): 8398-8402, 2005

Locoregional Control According to Breast Cancer Subtype and Response to Neoadjuvant Chemotherapy in Breast Cancer Patients Undergoing Breast-conserving Therapy. Annals of Surgical Oncology 23(3): 749-756, 2016

Breast Cancer Index predicts pathological complete response and eligibility for breast conserving surgery in breast cancer patients treated with neoadjuvant chemotherapy. Annals of Oncology 23(8): 2046-2052, 2012

Local-regional control according to surrogate markers of breast cancer subtypes and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast conserving therapy. Breast Cancer Research 14(3): R83-R83, 2013

Prospective validation of immunological infiltrate for prediction of response to neoadjuvant chemotherapy in HER2-negative breast cancer--a substudy of the neoadjuvant GeparQuinto trial. Plos One 8(12): E79775-E79775, 2014

Monitoring neoadjuvant chemotherapy in breast cancer patients: improved MR assessment at 3 T?. Journal of Magnetic Resonance Imaging 34(3): 547-556, 2012

Chemotherapy-induced amennorrhea: Predictive markers of response to neoadjuvant chemotherapy in breast cancer. Journal of Clinical Oncology 29(27_suppl): 281-281, 2016

Impact of Chemotherapy-Induced Ovarian Dysfunction on Response to Neoadjuvant Chemotherapy in Breast Cancer. Annals of Surgical Oncology 22 Suppl 3: S391-S397, 2016

Magnetic resonance imaging response monitoring of breast cancer during neoadjuvant chemotherapy: relevance of breast cancer subtype. Journal of Clinical Oncology 29(6): 660-666, 2011

Association of PIK3CA Mutation Status before and after Neoadjuvant Chemotherapy with Response to Chemotherapy in Women with Breast Cancer. Clinical Cancer Research 21(19): 4365-4372, 2016

Breast cancer subtyping by immunohistochemistry and histological grade outperforms breast cancer intrinsic subtypes in predicting neoadjuvant chemotherapy response. Breast Cancer Research and Treatment 140(1): 63-71, 2014